PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ...

* Indicates calculation not meaningful or results are greater than 100%. First-quarter 2025 Cost of Sales (2) as a percentage of revenues decreased by 2.0 percentage points compared to the prior-year ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 ...

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...